Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Intracellular signaling networks control cell growth and survival; their dysregulation is common in malignancies.
• The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway is crucial for cell proliferation and survival.
• Aberrant PI3K/mTOR signaling confers a survival advantage to cancer cells and can lead to chemotherapy resistance in hematologic malignancies.

Purpose of the Study:

• To discuss the dysregulation of the PI3K/mTOR signaling pathway in various hematologic malignancies.
• To review current and emerging PI3K/mTOR pathway inhibitors used in clinical trials.
• To emphasize the investigation of these inhibitors in pediatric hematologic malignancies.

Main Methods:

• Literature review of PI3K/mTOR signaling in hematologic malignancies.
• Analysis of current therapeutic strategies targeting the PI3K/mTOR pathway.
• Focus on ongoing clinical trials and drug development for pediatric hematologic malignancies.

Main Results:

• The PI3K/mTOR pathway is frequently dysregulated in hematologic cancers, including leukemias and lymphomas.
• Numerous small molecule inhibitors targeting the PI3K/mTOR pathway are under active investigation.
• Early-stage research shows promise for these inhibitors, especially in pediatric hematologic malignancies.

Conclusions:

• Targeting the PI3K/mTOR pathway represents a promising therapeutic strategy for hematologic malignancies.
• Continued investigation and development of PI3K/mTOR inhibitors are crucial for improving patient outcomes.
• Pediatric hematologic malignancies are a key focus for the clinical application of these novel therapies.